Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2013

View Archived Issues

SOMCL-12-81 as a potent ALK inhibitor with promising oncolytic activity

Dinaciclib plus MK-2206 evaluated in pancreatic cancer trial

Genethon discusses gene therapy for Wiskott-Aldrich syndrome, phase I/II results published

Roche and immatics biotechnologies sign cancer vaccine collaboration

PKM2 identified in ovarian serous adenocarcinoma samples

3-V Biosciences describes TVB-3166, a novel oncolytic FAS inhibitor

Epizyme's EPZ-5676 shows promise in an ongoing phase I trial

Acadia Pharmaceuticals begins pimavanserin trial for Alzheimer's disease psychosis

Enrollment complete in the DIRECT II study of Svelte Medical Systems' drug-eluting stent

Early clinical results presented for the novel antimalarial agent OZ-439

First patient treated in study of DNX-2401 and temozolomide for recurrent glioblastoma

Japanese researchers present novel Toll-like receptor antagonists

Defibrotide receives orphan drug status in Australia

New LRRK2 modulators patented by Genentech and Roche for Parkinson's disease

Takeda prepares new prostanoid EP2 receptor agonists

Spanish scientists divulge novel tamoxifen derivatives for cancer and other disorders

New DDR1 inhibitors for cancer disclosed by Chugai Pharmaceutical

Adocia begins trial of combination of long- and fast-acting insulin analogues

Sorrento to acquire antibody-drug conjugation technology from Concortis Biosystems

MicroBiome Therapeutics advances development of NM-504

Ono Pharmaceutical reports data from phase II/III study of ONO-2745

FDA advisory committee recommends approval of circadian regulator tasimelteon

Otsuka Pharmaceutical recaps highlights of second quarter of fiscal 2013

Novogen reports discovery in program for degenerative disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...